Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $102.96 USD
Change Today -0.78 / -0.75%
Volume 1.1M
INCY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Reid M. Huber Ph.D.

Chief Scientific Officer and Executive Vice President, Incyte Corporation
AgeTotal Calculated CompensationThis person is connected to 11 board members in 1 different organizations across 2 different industries.

See Board Relationships
43$2,242,534
As of Fiscal Year 2014

Background*

Dr. Reid M. Huber, Ph.D., has been Chief Scientific Officer and Executive Vice President of Incyte Corporation since May 2014. Dr. Huber leads drug discovery research primarily in the area of hematology/oncology. He served as Senior Vice President of Discovery Biology at Incyte Corporation. He was a founding member of the team that started drug discovery at Incyte Corporation in 2002. Dr. Huber joined Incyte in January 2002 as an Associate Director of Applied Technology. ...

Read Full Background

Corporate Headquarters*

1801 Augustine Cut-Off
Wilmington, Delaware 19803

United States

Phone: 302-498-6700
Fax: --

Board Members Memberships*

2014-Present
Director, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee

Education*

PhD
Washington University, St. Louis
BS
Murray State University

Other Affiliations*

Annual Compensation*

Salary$365,558
Total Annual Compensation$365,558

Stock Options*

Restricted Stock Awards$999,932
All Other Compensation$5,378
Exercised Options145,094
Exercised Options Value$7,853,217
Exercisable Options50,639
Exercisable Options Value$2,821,726
Unexercisable Options51,237
Unexercisable Options Value$1,788,010
Total Value of Options$12,462,952
Total Number of Options246,970

Total Compensation*

Total Annual Cash Compensation$642,624
Total Short Term Compensation$365,558
Other Long Term Compensation$1,005,310
Total Calculated Compensation$2,242,534
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INCY:US $102.96 USD -0.78

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Richard F. Pops Chairman of the Board and Chief Executive Officer
Alkermes plc
$854.7K
Harvey J. Berger M.D.Principal Founder, Chairman, Chief Executive Officer and President
Ariad Pharmaceuticals Inc.
$1.4M
Jean-Jacques Bienaime MBAChairman and Chief Executive Officer
BioMarin Pharmaceutical Inc.
$916.0K
Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
$1.1M
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
$830.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.